# Highly Specialised Technologies Evaluation Committee Meeting

Minutes: Confirmed

Date and Time: Thursday 11 April 2019

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

## **Present:**

1.Dr Peter Jackson Present for all notes

2.Sotiris Antoniou Present for all notes

3.Matt Smith Present for all notes

4.Paul Arundel Present for all notes

5.Sarah Davis Present for all notes

6.Stuart Davies Present for all notes

7.Carrie Gardner Present for all notes

8.Jeremy Manual Present for all notes

9.Francis Pang Present for all notes

10.Linn Phipps Present for all notes

11.Dr Mark Sheehan Present for all notes

## **In attendance:**

Helen Knight, Programme Director

National Institute for Health and Care Excellence Present for all notes

Sheela Upadhyaya Associate Director

National Institute for Health and Care Excellence Present for all notes

Joanne Ekeledo, Project Manager

National Institute for Health and Care Excellence Present for all notes

Lorna Dunning, Technical Analyst

National Institute for Health and Care Excellence Present for all notes

Ian Watson, Technical Adviser

National Institute for Health and Clinical Excellence Present for all notes

Samantha Barton, ERG representative - BMJ group Present for notes 1-8

Steve Edwards, ERG representative - BMJ group Present for notes 1-8

Neil Jackson, Patient representative Present for notes 1-8

Fiona Marley, NHS Commissioning expert) Present for notes 1-8

Karen O’Hara, Patient representative Present for notes 1-8

Prof David Parr, Clinical Representative Present for notes 1-8

Dr Alice Turner, Clinical Representative Present for notes 1-8

Dan Betts, Company representative (CSL Behring) Present for notes 1-8

Oliver Vit, Company representative (CSL Behring) Present for notes 1-8

## **Non-public observers:**

Alan Thomas, NICE, Appeal panel member Present for all notes

Sabrina Rind, AWTTC Present for all notes

Ben Doak, NHSE Present for all notes

Ann Greenwood, Editor, NICE Present for all notes

Mandy Tonkinson, PIP, NICE Present for all notes

Sohaib Ashraf, NICE observer Present for all notes

Yelan Guo, NICE observer Present for all notes

Emily Eaton, NICE observer Present for all notes

Lordanis Sidiropoulos, NICE observer Present for all notes

# Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the evaluation of Human alpha1-proteinase inhibitor for treating emphysema.
2. The Chair informed the Committee of the non-public observers at this meeting: Alan Thomas, Sabrina Rind, Ben Doak, Ann Greenwood, Mandy Tonkinson, Sohaib Ashraf, Yelan Guo, Emily Eaton and Lordanis Sidiropoulos.
3. Apologies were received from Professor Ron Akehurst, Dr Shehla Mohammed, Dr Glenda Sobey and Professor Lesley Stewart

Any other Business

1. None

# Evaluation of Human alpha1-proteinase inhibitor for treating emphysema [ID856]

## **Part 1 – Open session**

1. The Chair welcomed the invited experts: Samantha Barton, Steve Edwards, Neil Jackson, Fiona Marley, Karen O’Hara, Prof David Parr, and Dr Alice Turner to the meeting and they introduced themselves to the Committee.
2. The Chair welcomed company representatives from CSL Behring to the meeting.
3. The Chair asked all Committee members to declare any relevant interests
	1. All present Committee members declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the Evaluation of Human alpha1-proteinase inhibitor for treating emphysema.
4. The Chair asked all NICE Staff to declare any relevant interests.
	1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the evaluation of Human alpha1-proteinase inhibitor for treating emphysema.
5. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
	1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the evaluation of Human alpha1-proteinase inhibitor for treating emphysema.
6. The Chair introduced the key themes arising from the consultation responses to the Evaluation Consultation Document (ECD) received from consultees, commentators and through the NICE website.
7. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
8. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
9. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the evaluation and they left the meeting.

## **Part 2 – Closed session**

1. Discussion on confidential information continued. Clinical and patient experts, ERG and company representatives excused. This information was supplied by the company.
2. The Committee continued to discuss the clinical and cost effectiveness of Human alpha1-proteinase inhibitor for treating emphysema.
	1. The committee decision was based on consensus.
3. The Committee instructed the technical team to prepare the Evaluation Consultation Document (ECD)

# Date, time and venue of the next meeting

1. Tuesday 21 May 2019 10am at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT